What does this research mean for the field?

68Ga-FAPI demonstrates superior lesion detection and diagnostic accuracy compared to 18F-FDG PET/CT for recurrent ovarian cancer, particularly in the PARPi era. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

This research evaluates the effectiveness of 68Ga-FAPI compared to 18F-FDG PET/CT in recurrent ovarian cancer diagnosis during the PARP inhibitor treatment period.

March 14, 2026Open Access

68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era

Key Points

This research evaluates the effectiveness of 68Ga-FAPI compared to 18F-FDG PET/CT in recurrent ovarian cancer diagnosis during the PARP inhibitor treatment period.
Compared 68Ga-FAPI and 18F-FDG PET/CT in recurrent ovarian cancer patients.
Assessed lesion detection rates and diagnostic accuracy.
Investigated underlying mechanisms of resistance in FAPI+/FDG- lesions.
68Ga-FAPI showed superior lesion detection compared to 18F-FDG.
Enhanced diagnostic accuracy was observed in patients undergoing PARP inhibitor treatment.
Resistance mechanisms such as hypoglycolysis and CAF activation contribute to differing PET responses.

Abstract

68Ga-FAPI demonstrated superior lesion detection and diagnostic accuracy compared with 18F-FDG PET/CT for recurrent ovarian cancer, especially in the PARPi era. Hypoglycolysis and CAF activation may underlie PARPi resistance in FAPI+/FDG- lesions.

68Gallium-labelled FAP-inhibitors outperforms 18F-fluorodeoxyglucose PET/CT for recurrent ovarian cancer in the poly adenosine diphosphate-ribose polymerase inhibitor era

Key Points

Abstract

Cite This Study